Morphic to Participate in March Investor Conferences
2024年3月6日 - 6:05AM
Morphic Therapeutic (Nasdaq: MORF), a biotechnology company
developing a new generation of oral integrin therapies for the
treatment of serious chronic diseases, today announced its
participation at investor conferences during the month of March.
3/6/249:10 AM ETGI/Microbiome Panel Discussion
at the TD Cowen 44th Annual Health Care Conference
10:30 AM ETFireside Chat at the TD Cowen 44th Annual Health Care
Conference
3/13/24Jefferies Biotech on the Bay
SummitandLeerink Partners 2024 Global Biopharma Conference
A live webcast of the panel discussion and
fireside chat at the TD Cowen 44th Annual Health Care Conference
will be available on the Investor section of Morphic’s website
at www.morphictx.com. An archived replay will be available on
the company’s website following the conference.
About Morphic
TherapeuticMorphic Therapeutic is a biopharmaceutical
company developing a portfolio of oral integrin therapies for the
treatment of serious chronic diseases, including autoimmune,
cardiovascular, and metabolic diseases, fibrosis, and cancer.
Morphic is also advancing its pipeline and discovery activities in
collaboration with Schrödinger using its proprietary MInT
technology platform which leverages the Company’s unique
understanding of integrin structure and biology. For more
information, visit www.morphictx.com.
ContactsMorphic
TherapeuticChris Erdmanchris.erdman@morphictx.com617.686.1718
Morphic (NASDAQ:MORF)
過去 株価チャート
から 5 2024 まで 6 2024
Morphic (NASDAQ:MORF)
過去 株価チャート
から 6 2023 まで 6 2024